Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.
about
Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction.Variability in drug metabolizing enzyme activity in HIV-infected patients.Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activityFunctional evolution of the pregnane X receptor.Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.Interaction between midazolam and clarithromycin in the elderlyGender: a possible determinant in dosing of dermatologic drugs--an overview.Pharmacogenetics of the constitutive androstane receptor.Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.The missing linkage: what pharmacogenetic associations are left to find in CYP3A?CYP3A activity: towards dose adaptation to the individual.Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers.Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power.Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity.Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults.A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
P2860
Q33702513-2898C456-0CEA-46E2-95CA-F04C37890E2BQ33791508-4580EA92-23D3-47D6-8538-564B3CC18ECDQ35827674-09C69A27-270D-41B7-89AB-8B0AB3E3CC70Q36440155-98B6029E-1722-4B95-AB14-FA85719A2757Q36440873-3CFF7276-809E-4DAA-960A-33C05CB9AD2FQ36536037-3C9BA35E-DB9C-412F-9D6E-55F6D7CE9889Q36596188-F3877345-B5CF-48BA-887A-8FFAAEDD5289Q37043505-8CBE3AAF-61F7-4243-B1A1-2F7F03CD47FCQ37359687-40506B23-909A-4484-9D45-FB254943EB20Q37646778-78A0CD4C-C6DC-40B0-9470-B512F8528F06Q38763583-7F817E25-4CDF-4F92-B514-BB6EEE42B939Q42622286-298E5315-288B-40E0-8D61-CF66683E2C2CQ43626046-8E66EDA1-64F0-436C-AB72-8672B9E860EAQ43673452-3B30B0BD-0B9D-4C4F-B530-07F6910C9E2BQ43949796-8BEFE97F-B4F3-4EC8-96D4-ECF67C89931BQ44537853-18DEA948-90BD-41B3-8F81-2D0652FC12A5Q45151697-EBA2163A-4FB7-4918-8BC2-340ACA254079Q46807641-EF470010-87A5-410F-9F9B-3E5623486DD7Q46882770-312E6840-739D-498B-B3F7-673B2C7B2138Q46954390-AC9354CC-76B9-4481-9D87-DB8F9A6020EAQ48025123-C097EF62-8A37-4502-BE0A-9E933E3BAE03Q51452446-7C2B5521-D922-4ED3-8184-0D9C7AD43C02
P2860
Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Quantification of 3-month intr ...... ng with intravenous midazolam.
@en
Quantification of 3-month intr ...... ng with intravenous midazolam.
@nl
type
label
Quantification of 3-month intr ...... ng with intravenous midazolam.
@en
Quantification of 3-month intr ...... ng with intravenous midazolam.
@nl
prefLabel
Quantification of 3-month intr ...... ng with intravenous midazolam.
@en
Quantification of 3-month intr ...... ng with intravenous midazolam.
@nl
P2093
P1476
Quantification of 3-month intr ...... ng with intravenous midazolam.
@en
P2093
Bertino JS Jr
Kashuba AD
Nafziger AN
Rocci ML Jr
P304
P356
10.1016/S0009-9236(98)90175-8
P407
P577
1998-09-01T00:00:00Z